Add office photos
Engaged Employer
Dr. Reddy's
4.1
based on 6.5k Reviews
Company Overview
Associated Companies
Company Locations
Working at Dr. Reddy's
Company Summary
We are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’
Overall Rating
4.1/5
based on 6.5k reviews
15% above
industry average
Highly rated for
Skill Development, Company Culture, Work-Life Balance
Critically rated for
Promotions/Appraisal
Work Policy
Work from office
78% employees reported
Monday to Friday
39% employees reported
Flexible timing
67% employees reported
No travel
37% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
559 employees reported
Health insurance
467 employees reported
Cafeteria
307 employees reported
Child care facility
297 employees reported
View all benefits
About Dr. Reddy's
Founded in1984 (40 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersHyderabad/Secunderabad, Telangana, India
Office Locations
Websitedrreddys.com
Primary Industry
Other Industries
We started in 1984 with a modest investment and a bold vision. Today, with research and development centres, manufacturing facilities and commercial presence across the globe, we serve over half a billion patients worldwide. We aspire to triple our reach and touch over 1.5 billion patients by 2030.
We are committed to providing access to affordable and innovative medicines, driven by our purpose of ‘Good Health Can’t Wait’.
Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically-differentiated assets and digital healthcare.
Report error
Dr. Reddy's Subsidiaries
Aurigene Oncology Limited
4.4
• 225 reviews
Aurigene Pharmaceutical Services
4.1
• 195 reviews
SVAAS Wellness
4.0
• 11 reviews
Report error
AmbitionBox Best Places to Work in India Awards
Awards are based on 2021 reviews and ratings by employees of the company.
Congratulate
Know more
Share
Dr. Reddy's Ratings
based on 6.5k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.4k
4
1.8k
3
653
2
251
1
358
Category Ratings
4.0
Skill Development
3.9
Company Culture
3.9
Work-Life Balance
3.9
Salary & Benefits
3.7
Work Satisfaction
3.6
Job Security
3.4
Promotions/Appraisal
Dr. Reddy's is rated 4.1 out of 5 stars on AmbitionBox, based on 6.5k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Dr. Reddy's
based on 6.2k reviews
4.1
Rated by 704 Women
Rated 4.0 for Company Culture and 3.9 for Job Security
4.1
Rated by 5.5k Men
Rated 4.0 for Skill Development and 3.9 for Company Culture
Work Policy at Dr. Reddy's
based on 577 reviews in last 6 months
Work from office
78%
Hybrid
19%
Permanent work from home
3%
Dr. Reddy's Reviews
Top mentions in Dr. Reddy's Reviews
+ 5 more
Compare Dr. Reddy's with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.5k reviews | 3.9/5 based on 1.8k reviews | 4.1/5 based on 5.5k reviews | 4.1/5 based on 6.5k reviews |
Highly Rated for | Skill development Company culture Work-Life balance | Job Security Work-Life balance | Salary & Benefits Job Security Skill development | Skill development Salary & Benefits Work-Life balance |
Critically Rated for | Promotion/Appraisals | Promotion/Appraisals | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 78% employees reported | Work from office 83% employees reported | Work from office 87% employees reported | Work from office 72% employees reported |
Rating by Women Employees | 4.1 Good rated by 704 women | 3.9 Good rated by 258 women | 4.1 Good rated by 404 women | 4.1 Good rated by 627 women |
Rating by Men Employees | 4.1 Good rated by 5.5k men | 3.9 Good rated by 1.4k men | 4.1 Good rated by 4.8k men | 4.1 Good rated by 5.5k men |
Job Security | 3.6 Good | 3.8 Good | 3.9 Good | 3.7 Good |
View more
Dr. Reddy's Salaries
3.9
rated by 6.5k employees for salariesTeam Member
(4k salaries)
Unlock
₹1.8 L/yr - ₹9.8 L/yr
Analytical Scientist
(779 salaries)
Unlock
₹3 L/yr - ₹12.1 L/yr
Senior Team Member
(544 salaries)
Unlock
₹3.1 L/yr - ₹12 L/yr
Area Sales Manager
(471 salaries)
Unlock
₹5.2 L/yr - ₹12.7 L/yr
Team Lead
(431 salaries)
Unlock
₹7 L/yr - ₹23.9 L/yr
Scientist
(353 salaries)
Unlock
₹3.9 L/yr - ₹13 L/yr
Territory Manager
(328 salaries)
Unlock
₹2.5 L/yr - ₹7.2 L/yr
Formulation Scientist
(259 salaries)
Unlock
₹4 L/yr - ₹12.4 L/yr
Production Specialist
(252 salaries)
Unlock
₹3.2 L/yr - ₹7.5 L/yr
Research Associate
(252 salaries)
Unlock
₹2.2 L/yr - ₹10.5 L/yr
Dr. Reddy's Interview Questions
Interview questions by designation
Top interview questions and answers
Get interview-ready with top interview questions
Interview Process at Dr. Reddy's
based on 106 interviews in last 1 year
Interview Experience
4.3
Good
Difficulty level
Easy
20%
Moderate
70%
Hard
10%
People are getting interviews through
based on 259 Dr. Reddy's interviews
Job Portal
28%
Referral
21%
Walkin
15%
Company Website
8%
*28% candidates got the interview through other sources
High confidence
Dr. Reddy's Jobs
Dr. Reddy's News
View all
Nifty Pharma, Healthcare Snap Two-Day Fall Post Jefferies' Outlook
- Nifty Pharma and Nifty Healthcare snapped their two-day fall and rose on Tuesday, following a report by Jefferies on its takeaways from its tour of pharma companies across Delhi, Mumbai, and Hyderabad.
- The report mentioned that non-price metrics are being given due importance for supplier selection and hospitals are looking to add new geographies once the home turf is well protected.
- Indian generic firms with meaningful exposure to the US market are adopting different strategies to avoid price erosion, such as moving up the value chain and pursuing complex products.
- In Nifty Healthcare, Glenmark Pharma, Syngene International, and Apollo Hospitals were among the top gainers, while Dr Reddy's Labs, Zydus Lifesciences, and Aurobindo Pharma fell the most.
Bloomberg Quint | 10 Dec, 2024
Market dips slightly as RBI holds steady, signals economic caution
- The Sensex retreated 56.74 points or 0.07% to close at 81,709.12, while the Nifty 50 slipped 30.60 points or 0.12% to 24,677.80.
- Top gainers for the day included Tata Motors, Bajaj Auto, Axis Bank, BPCL, and Dr Reddy’s Lab.
- The RBI's MPC meeting highlighted optimism in growth revival and the strategic liquidity measures taken to stimulate economic growth.
- The market showed resilience in midcap and smallcap segments, and investors adopted a 'buy on dips' strategy.
HinduBusinessLine | 6 Dec, 2024
Stocks that will see action today - December 6
- Nykaa Fashion CEO Nihir Parikh resigns with immediate effect due to personal commitments.
- Dr Reddy's Laboratories subsidiary faces penalty of ₹28.7 lakh in Kazakhstan.
- Ola Electric receives communication from Central Consumer Protection Authority seeking additional documents and information.
- SEBI bars Mishtann Foods and its promoter from securities markets for financial mismanagement and fraudulent transactions.
HinduBusinessLine | 6 Dec, 2024
Dr Reddy’s launches nasopharyngeal carcinoma drug Toripalimab in India
- Dr Reddy’s launches nasopharyngeal carcinoma drug Toripalimab in India
- Toripalimab is the only immuno-oncology drug approved for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.
- Dr. Reddy’s has exclusive rights to develop and commercialize Toripalimab in 21 countries including India.
- India becomes the third country in the world to receive access to this next generation PD-1 inhibitor.
HinduBusinessLine | 28 Nov, 2024
Centrum Broking's Sumit Gupta Bets On Sun Pharma, Dr Reddy's—Here's Why
- Indian pharma companies are likely to gain in the long run from the emerging opportunities over the US Biosecure Act, according to Sumit Gupta, research analyst at Centrum Broking.
- Sun Pharmaceutical Industries Ltd. remains the top pick in the large-cap space, as well as Dr Reddy's Laboratories Ltd., considering the pipeline it has.
- Majority of the growth in the second quarter was led by US market-focussed companies while domestic pharma was subdued.
- Indian pharma companies may face potential tariffs imposed by President-elect Donald Trump, but the huge opportunity in the US market is likely to offset the impact.
Bloomberg Quint | 28 Nov, 2024
Buy, Sell Or Hold: BPCL, HAL, Exide Industries, Dr. Reddy's Laboratories, CDSL—Ask Profit
- Market experts shared their insights on whether investors should buy, sell, or hold shares of CDSL, IndusInd Bank, Exide Industries, Dr Reddy's Laboratories and BPCL, among others.
- Vaishali Parekh suggests to hold Dr Reddy's Laboratories as the long-term trend is still intact in the pharmaceutical sector.
- Sameer Dalal advises holding BPCL for now, as the oil refining business is expected to perform well, but recommends exiting after some time.
- Dalal also suggests holding CDSL, which is the largest player in its field and has strong operational leverage and growth opportunities.
- Parekh recommends buying Exide Industries, as it is technically well placed on the charts.
Bloomberg Quint | 27 Nov, 2024
Lupin recalls over 6 lakh bottles of hypertension drug in US: USFDA
- Lupin Pharmaceuticals Inc, a subsidiary of Lupin, is recalling over 6 lakh bottles of Ramipril capsules in the US.
- The recall is due to a manufacturing issue related to the active pharmaceutical ingredient sourced from an unapproved vendor.
- The affected lot consists of 2.5 mg, 5 mg, and 10 mg strength tablets manufactured at Lupin's Goa-based facility.
- Dr Reddy's Laboratories is also recalling 3,416 bottles of IBU 600 mg tablets in the US due to failed specifications.
HinduBusinessLine | 25 Nov, 2024
Dr Reddy’s, Aurobindo Pharma, Others To Build Facilities In Telangana’s Pharma City
- Six prominent pharmaceutical companies, including Dr Reddy's Laboratories, Aurobindo Pharma, and Hetero Labs, have signed MOUs with the Telangana government to set up facilities in the Pharma City near Hyderabad.
- The companies will invest over Rs 5,260 crore and create around 12,490 job opportunities in the pharma sector.
- The investments include establishing manufacturing units, formulation units, R&D centers, and injectables and drug substance manufacturing units.
- The construction work in the Pharma City is expected to begin within the next four months.
Bloomberg Quint | 23 Nov, 2024
Markets end higher despite late sell-off on Russia-Ukraine concerns
- Markets end higher despite late sell-off on Russia-Ukraine concerns
- The S&P BSE Sensex ended at 77,578.38, up 239.37 points or 0.31 per cent, while the NSE Nifty 50 settled at 23,518.50, gaining 64.70 points or 0.28 per cent.
- Markets started strong but experienced a sharp sell-off in the final trading hours after reports emerged of Ukraine launching strikes deep into Russian territory using Western missiles.
- Among the top gainers on the NSE, Mahindra & Mahindra led with a 3.15 per cent rise, followed by Tech Mahindra (1.88 per cent), HDFC Bank (1.81 per cent), Dr Reddy’s (1.66 per cent), and Eicher Motors (1.59 per cent).
HinduBusinessLine | 19 Nov, 2024
Markets extend losses for seventh day; IT stocks lead decline
- Markets extended losses for the seventh consecutive day, with IT stocks leading the decline.
- Selling pressure at higher levels erased early gains, and the IT sectoral index shed over 2%.
- Major losers included TCS (-3.11%), Dr Reddy’s Laboratories (-2.75%), and Infosys (-2.65%).
- The broader market showed mixed performance, with the metal index outperforming, while the IT index lost over 2%.
HinduBusinessLine | 18 Nov, 2024
Powered by
Dr. Reddy's Offices
Compare Dr. Reddy's with
Lupin
4.2
Zydus Lifesciences
4.2
Glenmark Pharmaceuticals
4.0
Torrent Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.8
Alembic Pharmaceuticals
4.0
Viatris
4.2
Abbott
4.2
Alkem Laboratories
3.9
Ipca Laboratories
4.0
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.3
GlaxoSmithKline Pharmaceuticals
4.1
Cadila Pharmaceuticals
3.5
Pfizer
4.0
Wockhardt
3.9
Piramal Group
3.9
Sanofi
4.3
Indoco Remedies
3.6
Contribute & help others!
You can choose to be anonymous
Companies Similar to Dr. Reddy's
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 5.5k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.5k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.8k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 5.8k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.2
• 5.8k reviews
Glenmark Pharmaceuticals
Pharma
4.0
• 2.7k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.4k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.6k reviews
DIVI'S Laboratories
Pharma
3.8
• 1.3k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 2.9k reviews
Dr. Reddy's FAQs
When was Dr. Reddy's founded?
Where is the Dr. Reddy's headquarters located?
How many employees does Dr. Reddy's have in India?
Does Dr. Reddy's have good work-life balance?
Is Dr. Reddy's good for career growth?
What are the pros and cons of working in Dr. Reddy's?
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
70 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
